Q2 EPS Forecast for Viridian Therapeutics Boosted by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – HC Wainwright lifted their Q2 2026 earnings estimates for Viridian Therapeutics in a note issued to investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($1.14) for the quarter, up from their prior estimate of ($1.22). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.73) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($3.20) EPS, FY2028 earnings at ($2.59) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at $0.90 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. Viridian Therapeutics’s revenue was up 95.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.87) EPS.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research report on Tuesday. Wedbush decreased their price objective on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Wells Fargo & Company decreased their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Finally, Truist Financial cut their target price on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $37.31.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $17.00 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.65 and a current ratio of 15.15. The stock has a market capitalization of $1.75 billion, a P/E ratio of -5.12 and a beta of 0.82. The company’s fifty day moving average is $21.57 and its two-hundred day moving average is $26.94. Viridian Therapeutics has a 1 year low of $11.98 and a 1 year high of $34.29.

Institutional Trading of Viridian Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Hudson Bay Capital Management LP increased its position in Viridian Therapeutics by 46.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after purchasing an additional 55,689 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Viridian Therapeutics by 135.6% during the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock valued at $25,922,000 after buying an additional 691,267 shares during the last quarter. Propel Bio Management LLC purchased a new position in shares of Viridian Therapeutics during the 3rd quarter valued at approximately $1,942,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Viridian Therapeutics by 430.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock valued at $1,394,000 after buying an additional 52,414 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Viridian Therapeutics during the 4th quarter valued at approximately $35,915,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.